APO-Imiquimod (Imiquimod)
imiquimod 5% cream, 12 x 250 mg sachets · APPLICATION · PBS code 2546B
AUTHORITY_REQUIREDWhat it costs
AU$70.25 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2012-12-01.
- • Repeats: 1.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Superficial basal cell carcinoma
The condition must be previously untreated; AND
The condition must be confirmed by biopsy; AND
Patient must have normal immune function; AND
The condition must not be suitable for treatment with surgical excision; or
The condition must not be suitable for treatment with cryotherapy; or
The condition must not be suitable for treatment with curettage with diathermy; AND
Patient must require topical drug therapy.
The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application.
Sponsor: Apotex Pty Ltd ABN 52 096 916 148
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.